MGMeir Glick

Meir Glick

*This is an algorithmically generated author record based on publicly available information.

Meir Glick has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Jeremy L. Jenkins

    Novartis Biomedical Research, Cambridge, MA, USA

    6 shared publications
  • John W. Davies

    Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States

    5 shared publications
  • Zhan Deng

    Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States

    4 shared publications
  • Andreas Bender

    Lead Discovery Informatics, Center for Proteomic Chemistry Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, Leiden/Amsterdam Center for Drug Research, Division of Medicinal Chemistry, Leiden, The Netherlands

    3 shared publications
  • Dmitri Mikhailov

    Lead Discovery Informatics, Lead Finding Platform, Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue, Cambridge, Massachusetts 02139

    3 shared publications
  • Josef Scheiber

    Institute of Medicinal and Pharmaceutical Chemistry, University of Technology Braunschweig , Beethovenstrasse 55, D 38106 Braunschweig, Germany

    3 shared publications

Latest Publications

  • Open Access

    Large Scale Meta-Analysis of Fragment-Based Screening Campaigns: Privileged Fragments and Complementary Technologies

    by Peter S. Kutchukian, Anne Mai Wassermann, Mika K. Lindvall, S. Kirk Wright, Johannes Ottl, Jaison Jacob, Clemens Scheufler, Andreas Marzinzik, Natasja Brooijmans, Meir Glick


  • Rethinking Molecular Similarity: Comparing Compounds on the Basis of Biological Activity

    by Paula M. Petrone, Benjamin Simms, Florian Nigsch, Eugen Lounkine, Peter Kutchukian, Allen Cornett, Zhan Deng, John W. Davies, Jeremy L. Jenkins, Meir Glick

    Since the advent of high-throughput screening (HTS), there has been an urgent need for methods that facilitate the interrogation of large-scale chemical biology data to build a mode of action (MoA) hypothesis. This can be done either prior to the HTS by subset design of compounds with known MoA or post HTS by data annotation and mining. To enable this process, we developed a tool that compares compounds solely on the basis of their bioactivity: the chemical biological descriptor “high-throughput screening fingerprint” (HTS-FP). In the current embodiment, data are aggregated from 195 biochemical and cell-based assays developed at Novartis and can be used to identify bioactivity relationships among the in-house collection comprising ∼1.5 million compounds. We demonstrate the value of the HTS-FP for virtual screening and in particular scaffold hopping. HTS-FP outperforms state of the art methods in several aspects, retrieving bioactive compounds with remarkable chemical dissimilarity to a probe structure. We also apply HTS-FP for the design of screening subsets in HTS. Using retrospective data, we show that a biodiverse selection of plates performs significantly better than a chemically diverse selection of plates, both in terms of number of hits and diversity of chemotypes retrieved. This is also true in the case of hit expansion predictions using HTS-FP similarity. Sets of compounds clustered with HTS-FP are biologically meaningful, in the sense that these clusters enrich for genes and gene ontology (GO) terms, showing that compounds that are bioactively similar also tend to target proteins that operate together in the cell. HTS-FP are valuable not only because of their predictive power but mainly because they relate compounds solely on the basis of bioactivity, harnessing the accumulated knowledge of a high-throughput screening facility toward the understanding of how compounds interact with the proteome.


  • Open Access

    A lead discovery strategy driven by a comprehensive analysis of proteases in the peptide substrate space

    by Sai Chetan K. Sukuru, Florian Nigsch, Jean Quancard, Martin Renatus, Rajiv Chopra, Natasja Brooijmans, Dmitri Mikhailov, Zhan Deng, Allen Cornett, Jeremy L. Jenkins, et al.


  • Open Access

    Plate-Based Diversity Selection Based on Empirical HTS Data to Enhance the Number of Hits and Their Chemical Diversity

    by Sai Chetan K. Sukuru, Jeremy L. Jenkins, Rohan E.J. Beckwith, Josef Scheiber, Andreas Bender, Dmitri Mikhailov, John W. Davies, Meir Glick


    • 1 May 2008
      • Vol. 11  (3) , 327-37

    Which aspects of HTS are empirically correlated with downstream success?

    by Andreas Bender, Dejan Bojanic, John W Davies, Thomas J Crisman, Dmitri Mikhailov, Josef Scheiber, Jeremy L Jenkins, Zhan Deng, W Adam G Hill, Maxim Popov, et al.

    High-throughput screening (HTS) is a well-established hit-finding approach used in the pharmaceutical industry. In this article, recent experience at Novartis with respect to factors influencing the success of HTS campaigns is discussed. An inherent measure of HTS quality could be defined by the assay Z and Z' factors, the number of hits and their biological potencies; however, such measures of quality do not always correlate with the advancement of hits to the later stages of drug discovery. Also, for many target classes, such as kinases, it is easy to identify hits, but, as a result of selectivity, intellectual property and other issues, the projects do not result in lead declarations. In this article, HTS success is defined as the fraction of HTS campaigns that advance into the later stages of drug discovery, and the major influencing factors are examined. Interestingly, screening compounds in individual wells or in mixtures did not have a major impact on the HTS success and, equally interesting, there was no difference in the progression rates of biochemical and cell-based assays. Particular target types, assay technologies, structure-activity relationships and powder availability had a much greater impact on success as defined above. In addition, significant mutual dependencies can be observed - while one assay format works well with one target type, this situation might be completely reversed for a combination of the same readout technology with a different target type. The results and opinions presented here should be regarded as groundwork, and a plethora of factors that influence the fate of a project, such as biophysical measurements, chemical attractiveness of the hits, strategic reasons and safety pharmacology, are not covered here. Nonetheless, it is hoped that this information will be used industry-wide to improve success rates in terms of hits progressing into exploratory chemistry and beyond. The support that can be obtained from new in silico approaches to phase transitions are also described, along with the gaps they are designed to fill.


  • “Virtual Fragment Linking”: An Approach To Identify Potent Binders from Low Affinity Fragment Hits

    by Thomas J. Crisman, Andreas Bender, Mariusz Milik, Jeremy L. Jenkins, Josef Scheiber, Sai Chetan K. Sukuru, Jasna Fejzo, Ulrich Hommel, John W. Davies, Meir Glick

    In this work we explore the possibilities of using fragment-based screening data to prioritize compounds from a full HTS library, a method we call virtual fragment linking (VFL). The ability of VFL to identify compounds of nanomolar potency based on micromolar fragment binding data was tested on 75 target classes from the WOMBAT database and succeeded in 57 cases. Further, the method was demonstrated for seven drug targets from in-house screening programs that performed both FBS of 8800 fragments and screens of the full library. VFL captured between 28% and 67% of the hits (IC50 < 10µM) in the top 5% of the ranked library for four of the targets (enrichment between 5-fold and 13-fold). Our findings lead us to conclude that proper coverage of chemical space by the fragment library is crucial for the VFL methodology to be successful in prioritizing HTS libraries from fragment-based screening data.


  • Open Access

    “Plate Cherry Picking”: A Novel Semi-Sequential Screening Paradigm for Cheaper, Faster, Information-Rich Compound Selection

    by Thomas J. Crisman, Jeremy L. Jenkins, Christian N. Parker, W. Adam G. Hill, Andreas Bender, Zhan Deng, James H. Nettles, John W. Davies, Meir Glick